Evotec is to receive funding of up to EUR1.5m (GBP1.3m) from the German Federal Ministry of Education and Research (BMBF) to advance its H3 receptor antagonist programme into the clinic.
Using its CNS experience coupled with its discovery platform, Evotec has identified and optimised H3 receptor antagonists through to preclinical development.
This grant will provide external funding for Evotec to advance the programme through Phase I clinical studies.
There is evidence that blocking the histamine H3 receptor in the brain can improve cognition, alertness and attention.
Therefore, H3 receptor antagonists have the potential to become an important class of therapy in a number of CNS indications, including excessive fatigue associated with conditions such as multiple sclerosis, according to the company.
